NovaBridge Biosciences
NBP
$3.89
$0.000.00%
NASDAQ
| 09/30/2025 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 246.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 246.86% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 246.86% | |||
| SG&A Expenses | 52.17% | 81.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.36% | 223.56% | |||
| Operating Income | -26.36% | -223.25% | |||
| Income Before Tax | -24.06% | -466.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.06% | -466.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.06% | -129.21% | |||
| EBIT | -26.36% | -223.25% | |||
| EBITDA | -26.44% | -240.69% | |||
| EPS Basic | 2.77% | -128.61% | |||
| Normalized Basic EPS | 2.85% | -- | |||
| EPS Diluted | 2.77% | -128.80% | |||
| Normalized Diluted EPS | 2.85% | -- | |||
| Average Basic Shares Outstanding | 27.55% | 0.27% | |||
| Average Diluted Shares Outstanding | 27.55% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||